Inspire's Denufosol Moves To Phase III For Cystic Fibrosis
This article was originally published in The Pink Sheet Daily
Executive Summary
The clinical program will include two pivotal efficacy studies and long-term carcinogenicity study.
You may also be interested in...
Inspire Begins Phase III Trial Of Denufosol Tetrasodium For Cystic Fibrosis
The firm must complete the 48-week study before submitting an NDA for inhaled denufosol.
Inspire Begins Phase III Trial Of Denufosol Tetrasodium For Cystic Fibrosis
The firm must complete the 48-week study before submitting an NDA for inhaled denufosol.
Pharmaxis To Expedite Bronchitol Phase III Program In Cystic Fibrosis
Pharmaxis preps for pivotal studies of mannitol after Phase II trials showed lung function improvement.